Top Suppliers:I want be here

1802909-49-4

1802909-49-4 structure
1802909-49-4 structure
  • Name: INCB059872
  • Chemical Name: INCB059872
  • CAS Number: 1802909-49-4
  • Molecular Formula: C23H34N2O3
  • Molecular Weight: 386.53
  • Catalog: Signaling Pathways Epigenetics Histone Demethylase
  • Create Date: 2021-10-18 18:54:24
  • Modify Date: 2024-01-09 08:13:52
  • INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia[1].

Name INCB059872
Description INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia[1].
Related Catalog
Target

LSD1[1]

In Vitro INCB059872 (25 nM; 48 hours; 293T cells) increases enhancer activity and gene expression[1]. INCB059872 (25 nM; 24 hours; THP-1 cells) makes THP-1 show a growth defect within one cell doubling time or approximately 3 days. INCB059872 (100 nM; 24 hours; MV-4–11 cells) treated MV-4–11 cells continues to grow as DMSO-treated cells for multiple cell divisions. INCB059872 (THP-1 cells) regulates PRO-seq analysis identifies genes and enhancers[1]. Western Blot Analysis[1] Cell Line: 293T cells Concentration: 250 nM Incubation Time: 48 hours Result: Increased enhancer activity and gene expression.
In Vivo INCB059872 (10 mg/kg; p.o.; 0, 4, or 6 days) makes single-cell RNA-seq revealing changes in bone marrow progenitor populations[1]. Animal Model: Mice[1] Dosage: 10 mg/kg Administration: P.o.; 0, 4, or 6 days Result: Single-cell RNA-seq revealed changes in bone marrow progenitor populations.
References

[1]. Johnston G, et al. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia. Gene. 2020;752:144758.

Molecular Formula C23H34N2O3
Molecular Weight 386.53